Pfizer FY2026 Earnings Forecast Raised by Erste Group Bank

Key Points

• Erste Group Bank raised Pfizer’s FY2026 EPS forecast slightly to $2.97 from $2.96, broadly in line with the $2.96 analyst consensus; Pfizer’s own guidance is $2.80–$3.00 per share.
• Pfizer’s latest quarterly results beat expectations, with EPS of $0.77 versus $0.68 expected and revenue of $15.03 billion versus $14.40 billion. Shares recently traded at $28.39, while analysts maintain a consensus “Hold” rating and an average price target of $28.72.
• The company declared a quarterly dividend of $0.43 per share, equivalent to $1.72 annually and a 6.1% yield, although its payout ratio remains elevated at 226.32%.

Pfizer Inc. (NYSE:PFE - Free Report) - Equities researchers at Erste Group Bank raised their FY2026 EPS estimates for Pfizer in a report released on Thursday, October 8th. Erste Group Bank analyst H. Engel now anticipates that the biopharmaceutical company will post earnings of $2.97 per share for the year, up from their prior estimate of $2.96. The consensus estimate for Pfizer's current full-year earnings is $2.96 per share.

PFE has been the topic of a number of other research reports. BMO Capital Markets reduced their price objective on Pfizer from $34.00 to $30.00 and set an "outperform" rating on the stock in a research note on Monday, July 13th. Scotiabank raised their target price on Pfizer from $30.00 to $33.00 and gave the company an "outperform" rating in a research note on Tuesday, October 6th. Cantor Fitzgerald lifted their price target on Pfizer from $27.00 to $28.00 and gave the company a "neutral" rating in a report on Thursday, October 8th. HSBC upped their price target on shares of Pfizer from $28.00 to $30.00 and gave the stock a "hold" rating in a research report on Thursday, September 10th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Pfizer from $28.00 to $30.00 and gave the stock a "neutral" rating in a report on Friday. Five equities research analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $28.72.

Pfizer Trading Up 0.4%

Shares of PFE opened at $28.39 on Tuesday. The stock has a fifty day moving average price of $27.75 and a two-hundred day moving average price of $26.51. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27. Pfizer has a 52-week low of $23.62 and a 52-week high of $29.21. The company has a market cap of $161.82 billion, a price-to-earnings ratio of 37.36, a PEG ratio of 1.91 and a beta of 0.32.

Pfizer (NYSE:PFE - Get Free Report) last announced its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, topping the consensus estimate of $0.68 by $0.09. The business had revenue of $15.03 billion for the quarter, compared to the consensus estimate of $14.40 billion. Pfizer had a return on equity of 19.63% and a net margin of 6.80%. Pfizer's revenue was up 2.6% compared to the same quarter last year. During the same period in the previous year, the business earned $0.78 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS.

Institutional Investors Weigh In On Pfizer

Large investors have recently modified their holdings of the business. Retirement Wealth Solutions LLC boosted its holdings in shares of Pfizer by 144.6% during the 3rd quarter. Retirement Wealth Solutions LLC now owns 861 shares of the biopharmaceutical company's stock worth $25,000 after buying an additional 509 shares in the last quarter. Evolution Wealth Management Inc. increased its stake in shares of Pfizer by 132.2% in the 1st quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company's stock valued at $28,000 after acquiring an additional 566 shares in the last quarter. Keb Asset Management LLC bought a new stake in shares of Pfizer in the 2nd quarter valued at $26,000. Field & Main Bank acquired a new position in shares of Pfizer during the 2nd quarter valued at $27,000. Finally, Global Trust Asset Management LLC lifted its position in shares of Pfizer by 126.7% during the 1st quarter. Global Trust Asset Management LLC now owns 1,163 shares of the biopharmaceutical company's stock valued at $33,000 after acquiring an additional 650 shares during the period. 68.36% of the stock is currently owned by institutional investors.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 7th. Shareholders of record on Friday, November 6th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.1%. The ex-dividend date of this dividend is Friday, November 6th. Pfizer's payout ratio is presently 226.32%.

Pfizer Company Profile

Pfizer Inc NYSE: PFE is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research and commercial activities focus on areas including oncology, inflammation and immunology, internal medicine, hospital care and vaccines.

The company's portfolio includes widely used products such as the Prevnar family of pneumococcal vaccines, Ibrance for certain breast cancers, Eliquis for preventing blood clots, Xeljanz for inflammatory conditions, and Vyndaqel for transthyretin amyloidosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.